Table 2.
Initial ASM administered in 236 patients with glioma
| Patient number (percentage of total) * | |
|---|---|
| LEV | 75 (31.8) |
| ZNS | 64 (27.1) |
| VPA | 37 (15.7) |
| CBZ | 17 (7.2) |
| PHT | 17 (7.2) |
| CLB | 4 (1.7) |
| LTG | 4 (1.7) |
| GBP | 4 (1.7) |
| PB | 3 (1.3) |
| Unknown** | 18 (7.6) |
* Patients who had been administered multiple ASMs at the previous hospital were counted under each ASM (VPA and ZNS, 2 patients; LEV and GBP, 2; LEV and VPA, 2; PB and PHT,1; LTG and ZNS, 1; PHT and ZNS, 1)
** Patients classed as “unknown” were those who had been treated at other hospitals for a long time and had an uncertain medication history
ASM, antiseizure medication; LEV, levetiracetam; ZNS, zonisamide; VPA, valproic acid; CBZ, carbamazepine; PHT, phenytoin; CLB, clobazam; PER, perampanel; LTG, lamotrigine; GBP, gabapentin; PB, phenobarbital.